426 results on '"Avalos, Belinda"'
Search Results
2. Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy
3. Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies
4. Survival following allogeneic transplant in patients with myelofibrosis
5. Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia
6. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant
7. Altered expression of CSF3R splice variants impacts signal response and is associated with SRSF2 mutations
8. Hematopoietic Growth Factors in the Supportive Care and Treatment of Patients with Hematologic Neoplasms
9. Allogeneic hematopoietic cell transplantation; the current renaissance
10. Transplantation and cellular therapy in acute leukemia
11. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing
12. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials
13. Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics
14. Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation
15. Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation
16. Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study
17. Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival
18. Heterodimerization of CSF3R Splice Variants and Mutants Alter Receptor Function
19. Hematopoietic Growth Factors in the Supportive Care and Treatment of Patients with Hematologic Neoplasms
20. Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax
21. Hematopoietic Growth Factors in the Supportive Care and Treatment of Patients with Hematologic Neoplasms
22. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
23. How Many Stem Cells Are Sufficient for Engraftment?
24. Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)
25. Can G-CSF Cause Leukemia in Hematopoietic Stem Cell Donors?
26. Clinical Characteristics and Outcomes of AML Patients Treated with Frontline CPX 351 or HMA/Venetoclax: A Single Institution's Experience
27. Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients
28. Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant Have Worse Outcomes, Similar to Active Disease Regardless of Conditioning Regimen Intensity and Post-Transplant Cyclophosphamide Administration
29. CSF3R Splicing Regulates Granulopoiesis Via Splice Variant Specific Responses to G-CSF
30. Aurora Kinase Inhibition Overcomes Primary Venetoclax Failure and Leads to Synthetic Lethality in BCL2-Positive Lymphomas Via Upregulation of P53/P21/BAX Axis
31. Incidence and Risk Factors Associated with Fatal Graft Vs Host Disease after Solid Organ Transplantation in United Network of Organ Transplant Database
32. Platform Incorporating Patient Navigation, Preparative Guidelines, and Hospital at Home May Improve COVID-19 Outcomes for Patients with Myeloid Malignancies
33. Hereditary Chronic Neutrophilic Leukemia in a Four Generation Family without Transformation to Acute Leukemia
34. Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B‐cell lymphoma
35. Late Mortality and Relapse following BuCy2 and HLA-Identical Sibling Marrow Transplantation for Chronic Myelogenous Leukemia
36. An Update on Stem Cell Transplantation in Autoimmune Rheumatologic Disorders
37. Role of the proteasome in modulating native G-CSFR expression
38. Should busulfan now be part of the standard treatment for patients with acute myeloid leukemia?
39. Altered splicing and intronic polyadenylation of CSF3R via a cryptic exon in acute myeloid leukemia
40. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation
41. Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients
42. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
43. Complex CSF3R Protein Isoform Interactions Dictate Cytokine Responsiveness
44. Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients
45. Characteristics Affecting Durability and Tolerability of Imatinib in Patients Switched from Brand to Generic and Newly Diagnosed Patients Initially Prescribed Generic Imatinib for Chronic Myeloid Leukemia
46. Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative
47. Hematopoietic Growth Factors in the Supportive Care and Treatment of Patients with Hematologic Neoplasms
48. Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation
49. High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation
50. Abstract 1920: Response to hypomethylating agents based on cytidine deaminase expression, genetic polymorphisms, and NPM1 mutation status in acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.